基本數據
| CIK | 1739410 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rallybio Corporation
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 1, 2026 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-10.4 Exhibit 10.4 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [•] (the “Effective Date”), is entered into by and between Rallybio Corporation, a Delaware corporation (“Rallybio”), and [•], a [•], as Rights Agent (as defined herein). RECITALS A. Rallybio, Farmington Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission File |
|
| June 1, 2026 |
EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (THIS “AGREEMENT”) is made as of May 31, 2026, by and between AVENZO THERAPEUTICS, INC., a Delaware corporation (“Company”), and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.0001 per share (“Common Stock” |
|
| June 1, 2026 |
EX-10.6 Exhibit 10.6 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 31, 2026, is entered into by and among Avenzo Therapeutics, Inc., a Delaware corporation, Rallybio Corporation, a Delaware corporation (the “Parent”), and the several investors signatory hereto (individually as a “Purchaser” and collectively together with their respective permi |
|
| June 1, 2026 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.8 Exhibit 10.8 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This second amendment (this “Amendment”) amends the Employment Agreement (the “Agreement”), dated as of February 1, 2023, as amended by that certain Amendment to Employment Agreement (the “First Amendment”), between Rallybio Corporation, a Delaware corporation (the “Company”), and Jonathan I. Lieber (the “Executive”) and is effective as |
|
| June 1, 2026 |
EX-99.3 Exhibit 99.3 Avenzo Therapeutics and Rallybio Corporation Merger Agreement + Concomitant Private Placement Announcement Webcast Call Transcript Date: June 1, 2026 Time: 8:30 AM ET CORPORATE PARTICIPANTS Dr. Stephen Uden, M.D., Co-Founder and Chief Executive Officer, Rallybio Corporation Dr. Athena Countouriotis, M.D., Chair, President and Chief Executive Officer, Avenzo Therapeutics, Inc. |
|
| June 1, 2026 |
EX-2.1 Exhibit 2.1 STRICTLY CONFIDENTIAL Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: RALLYBIO CORPORATION, a Delaware corporation; FARMINGTON MERGER SUB, INC., a Delaware corporation; and AVENZO THERAPEUTICS, INC., a Delaware corporation Dated as of May 31, 2026 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 |
|
| June 1, 2026 |
EX-10.2 Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (THIS “AGREEMENT”) is made as of May 31, 2026, by and between RALLYBIO CORPORATION, a Delaware corporation (“Parent”), and the [Person] set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of class A common stock, par value $0.0001 per share (“Common St |
|
| June 1, 2026 |
AMENDMENT TO CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT EX-10.9 Exhibit 10.9 AMENDMENT TO CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT This amendment (this “Amendment”) amends the Confidential Release and Separation Agreement (the “Agreement”), dated as of March 31, 2026, between Rallybio Corporation, a Delaware corporation (the “Company”), and Steven Ryder (“Dr. Ryder”) and is effective as of the date set forth on the signature page hereto. Except as |
|
| June 1, 2026 |
EX-99.1 Exhibit 99.1 Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Combined company to operate as Avenzo Therapeutics, advancing a leading portfolio of next-generation oncology therapies, including small molecules and antibody-drug conjugates Concurrent oversubscribed private placem |
|
| June 1, 2026 |
EX-10.5 Exhibit 10.5 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made and entered into as of May 31, 2026 (the “Effective Date”) by and among Avenzo Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a “Purchaser” and together the “Purchasers”). Certain terms used |
|
| June 1, 2026 |
EX-99.2 Exhibit 99.2 Avenzo Therapeutics Transaction and Company Overview June 1, 2026 1 Disclaimer This presentation and the accompanying slides and oral commentary (this “Presentation”), which have been prepared by Avenzo Therapeutics, Inc. (the “Company” or “Avenzo”), are being delivered and/or presented to a limited number of parties for discussion purposes only, and shall not form the basis f |
|
| June 1, 2026 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission F |
|
| June 1, 2026 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.7 Exhibit 10.7 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This second amendment (this “Amendment”) amends the Second Amended and Restated Employment Agreement (the “Agreement”), dated as of August 1, 2023, as amended by that certain Amendment to Employment Agreement (the “First Amendment”), between Rallybio Corporation, a Delaware corporation (the “Company”), and Stephen Uden (the “Executive”) |
|
| June 1, 2026 |
Lock-Up Agreement May 31, 2026 EX-10.3 Exhibit 10.3 Lock-Up Agreement May 31, 2026 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) RALLYBIO CORPORATION., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026 (the “Merger Agreement”), with AVENZO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and FARMINGTON MER |
|
| May 13, 2026 |
CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT Exhibit 10.1 CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT This Confidential Release and Separation Agreement (“Agreement”) is made by and between Steven Ryder, M.D. (“Employee” or “you”), on behalf of yourself and your agents, assignees, heirs, executors, administrators, beneficiaries, trustees, legal representatives and assigns (collectively “Employee Parties”), and Rallybio Corporation, its sub |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 5, 2026 |
RALLYBIO CORPORATION 234 Church Street New Haven, Connecticut 06510 RW RALLYBIO CORPORATION 234 Church Street New Haven, Connecticut 06510 May 5, 2026 VIA EDGAR U. |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 4, 2026 |
EX-2.1 Exhibit 2.1 Confidential WAIVER This Waiver (this “Waiver”), dated as of May 1, 2026, to the Agreement (as defined below) is executed and delivered by Rallybio Corporation, a Delaware corporation (“Parent”), Candid Therapeutics, Inc., a Delaware corporation (the “Company”) and UCB S.A. (“UCB”). Capitalized terms used but not otherwise defined in this Waiver shall have the same meanings ascr |
|
| April 24, 2026 |
CONSENT OF CITIZENS JMP SECURITIES, LLC EX-99.1 Exhibit 99.1 CONSENT OF CITIZENS JMP SECURITIES, LLC We hereby consent to the use of our opinion letter, dated March 1, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form S-4 of Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026. S-4/A No. 1 Table of Contents As filed with the Securities and Exchange Commission on April 24, 2026. Registration No. 333-294361 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment NO. 1 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RALLYBIO CORPORATION (Exact name of registrant as specified in its Charter) Delaware 2834 85-1083789 (State or other |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 17, 2026 |
CANDID THERAPEUTICS, INC. FORM OF COMMON STOCK PURCHASE AGREEMENT EX-10.30 Exhibit 10.30 CANDID THERAPEUTICS, INC. FORM OF COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”) is made as of [ ] by and between Candid Therapeutics, Inc., a Delaware corporation (the “Company”) and [ ] (“Purchaser”). Certain capitalized terms used below are defined in the terms and conditions set forth in Exhibit A attached to this Agreement, |
|
| March 17, 2026 |
EX-10.38 Exhibit 10.38 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of January 2, 2025 (the “Effective Date”), by and between CAN |
|
| March 17, 2026 |
Calculation of Filing Fee Tables S-4 Rallybio Corp Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| March 17, 2026 |
EX-10.32 Exhibit 10.32 7/12/2024 Candid Therapeutics, Inc. 11622 El Camino Real, Suite 150, San Diego, California 92130 Re: Employment Terms Dear Bernard: Candid Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on 7/16/2024 (the “Start Date”). Position Your initial position will be Chief Technical Officer, responsible for performing such duties as are assigned to you |
|
| March 17, 2026 |
EX-10.31 Exhibit 10.31 7/1/2024 Candid Therapeutics, Inc. 11622 El Camino Real, Suite 150, San Diego, California 92130 Re: Employment Terms Dear Ken: Candid Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on 7/1/2024 (the “Start Date”). Position Your initial position will be President and Chief Executive Officer, responsible for performing such duties as are assigne |
|
| March 17, 2026 |
LICENSE AND COLLABORATION AGREEMENT EX-10.36 Confidential Execution Draft Exhibit 10.36 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into |
|
| March 17, 2026 |
EX-10.33 Exhibit 10.33 7/17/2024 Candid Therapeutics, Inc. 11622 El Camino Real, Suite 150, San Diego, California 92130 Re: Employment Terms Dear Tim: Candid Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on 7/22/2024 (the “Start Date”). Position Your initial position will be Chief Medical Officer and Chief Scientific Officer, responsible for performing such duties |
|
| March 17, 2026 |
EX-10.37 Exhibit 10.37 OFFICE LEASE AGREEMENT BETWEEN PACIFIC NORTH COURT HOLDINGS, L.P. AS LANDLORD AND CANDID THERAPEUTICS, INC. AS TENANT - 1 - STANDARD FORM MODIFIED GROSS OFFICE LEASE This Standard Form Modified Gross Office Lease (“Lease”) is entered into effective as of June 27, 2024, between PACIFIC NORTH COURT HOLDINGS, L.P., a California limited partnership (“Landlord”), and CANDID THERA |
|
| March 17, 2026 |
Table of Contents As filed with the Securities and Exchange Commission on March 16 , 2026. |
|
| March 17, 2026 |
EX-10.35 Exhibit 10.35 CONFIDENTIAL Execution Version CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of August 2, 2024 (the “Effect |
|
| March 17, 2026 |
EX-10.28 Exhibit 10.28 INDEMNIFICATION AGREEMENT This Indemnification Agreement is dated as of (this “Agreement”) and is between Candid Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned (“Indemnitee”). Background The Company believes that in order to attract and retain highly competent persons to serve as directors or in other capacities, including as officers, it mus |
|
| March 17, 2026 |
EX-10.29 Exhibit 10.29 CANDID THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: May 1, 2024 APPROVED BY THE STOCKHOLDERS: May 1, 2024 AMENDED BY THE BOARD OF DIRECTORS: June 1, 2024 APPROVED BY THE STOCKHOLDERS: June 1, 2024 AMENDED BY THE BOARD OF DIRECTORS: August 19, 2024 APPROVED BY THE STOCKHOLDERS: August 19, 2024 TERMINATION DATE: May 1, 2034 1. General. (a) E |
|
| March 17, 2026 |
CONSENT OF CITIZENS JMP SECURITIES, LLC EX-99.1 Exhibit 99.1 CONSENT OF CITIZENS JMP SECURITIES, LLC We hereby consent to the use of our opinion letter, dated March 1, 2026, to the Board of Directors of Rallybio Corporation, included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form S-4 of Rallybio Corporation, to be filed on the date hereof, and to the references to such opinion in |
|
| March 17, 2026 |
EX-10.34 Exhibit 10.34 7/23/2024 Candid Therapeutics, Inc. 11622 El Camino Real, Suite 150, San Diego, California 92130 Re: Employment Terms Dear Arvind: Candid Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on 7/29/2024 (the “Start Date”). Position Your initial position will be Chief Financial Officer and Chief Business Officer, responsible for performing such dut |
|
| March 16, 2026 |
RALLYBIO CORPORATION POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION Exhibit 97 RALLYBIO CORPORATION POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1. |
|
| March 16, 2026 |
Exhibit 19.1 Insider Trading Policy 1.Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Rallybio Corporation (the “Company”) and the handling of confidential information about the Company and the companies with which it does business. The Company’s Board of Directors (the “Board”) has adopted this Policy to promote compliance |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| March 2, 2026 |
EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (THIS “AGREEMENT”) is made as of March 1, 2026, by and between RALLYBIO CORPORATION, a Delaware corporation (“Parent”), and the [Person] set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.0001 per share (“Common Stock”) a |
|
| March 2, 2026 |
Lock-Up Agreement March 1, 2026 EX-10.3 Exhibit 10.3 Lock-Up Agreement March 1, 2026 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) RALLYBIO CORPORATION., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of March 1, 2026 (the “Merger Agreement”), with CANDID THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Farmington M |
|
| March 2, 2026 |
EX-2.1 Exhibit 2.1 STRICTLY CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: RALLYBIO CORPORATION, a Delaware corporation; FARMINGTON MERGER SUB, INC., a Delaware corporation; and CANDID THERAPEUTICS, INC., a Delaware corporation Dated as of March 1, 2026 TABLE OF CONTENTS Section 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 |
|
| March 2, 2026 |
EX-10.5 Exhibit 10.5 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made and entered into as of March 1, 2026 (the “Effective Date”) by and among Candid Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a “Purchaser” and together the “Purchasers”). Certain terms used |
|
| March 2, 2026 |
Candid Therapeutics and Rallybio Corporation EX-99.3 Exhibit 99.3 Candid Therapeutics and Rallybio Corporation Merger Agreement + Concomitant Private Placement Announcement Webcast Call Transcript Date: Monday, March 2, 2026 Time: 8:30 AM ET CORPORATE PARTICIPANTS Dr. Stephen Uden, M.D., Co-Founder and Chief Executive Officer, Rallybio Corporation Dr. Ken Song, M.D., Chairman, President and Chief Executive Officer, Candid Therapeutics, Inc. |
|
| March 2, 2026 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.6 Exhibit 10.6 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) amends the Second Amended and Restated Employment Agreement (the “Agreement”), dated as of August 1, 2023, between Rallybio Corporation, a Delaware corporation (the “Company”) and Stephen Uden (the “Executive”) and is effective as of the execution of that certain Agreement and Plan of Merger, dated as of on or |
|
| March 2, 2026 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.7 Exhibit 10.7 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) amends the Employment Agreement (the “Agreement”), dated as of February 1, 2023, between Rallybio Corporation, a Delaware corporation (the “Company”) and Jonathan Lieber (the “Executive”) and is effective as of the execution of that certain Agreement and Plan of Merger, dated as of on or about the date hereof, |
|
| March 2, 2026 |
EX-99.2 Transaction and Company Overview March 2, 2026 Exhibit 99.2 Disclaimer This presentation and the accompanying slides and oral commentary (this “Presentation”), which have been prepared by Candid Therapeutics, Inc. (the “Company”), are for informational purposes only, and shall not form the basis for or be relied on in connection with any investment decision with respect to the Company, Ral |
|
| March 2, 2026 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission |
|
| March 2, 2026 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-10.4 Exhibit 10.4 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of March 1, 2026 (the “Effective Date”), is entered into by and between Rallybio Corporation, a Delaware corporation (“Rallybio”), and [•], a [•], as Rights Agent (as defined herein). RECITALS A. Rallybio, Farmington Merger Sub, Inc., a Delaware corporation and a wholly owned |
|
| March 2, 2026 |
EX-10.2 Exhibit 10.2 Execution Version SUPPORT AGREEMENT This SUPPORT AGREEMENT (THIS “AGREEMENT”) is made as of March 1, 2026, by and between CANDID THERAPEUTICS, INC., a Delaware corporation (“Company”), and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.0001 per sh |
|
| March 2, 2026 |
EX-99.1 Exhibit 99.1 Rallybio Corporation and Candid Therapeutics Announce Merger Agreement Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds |
|
| March 2, 2026 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.8 Exhibit 10.8 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) amends the Employment Agreement (the “Agreement”), dated as of June 25, 2025, between Rallybio Corporation, a Delaware corporation (the “Company”) and Steven Ryder, M.D. (the “Executive”) and is effective as of the execution of that certain Agreement and Plan of Merger, dated as of on or about the date hereof, |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission File |
|
| January 29, 2026 |
CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION RALLYBIO CORPORATION, a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Rallybio Corporation (the “Corporation”). The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2026 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 2, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| December 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 6, 2025 |
Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the registrant customarily and actually treats such information as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “A |
|
| November 6, 2025 |
, 2025 regarding financial results for the quarter ended Exhibit 99.1 Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – NEW HAVEN, Conn., November 6, 2025 - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
Exhibit 99.1 Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates – Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively – – Sold Interest in REV102 to Recursion Pharmaceuticals for Up to $25 Million, including an Upfront Equity Payment of $7.5 Million – – Cash Runway into Mid-2027 – NEW HAVEN, Conn., |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 8, 2025 |
Exhibit 99.1 Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals – Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn., July 8, 2025 - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapi |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 27, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of June 25, 2025 (the “Effective Date”) by and between Rallybio, LLC, a Delaware limited liability company (the “Company”), Rallybio Corporation, a Delaware corporation (“Parent”), and Steven Ryder, M.D. (the “Executive”). W I T N E S S E T H: WHEREAS, the Company desires to continue to employ the Executive as the C |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| May 9, 2025 |
As filed with the Securities and Exchange Commission on May 9, 2025 As filed with the Securities and Exchange Commission on May 9, 2025 Registration No. |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 8, 2025 |
Exhibit 99.1 Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates – On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – NEW HAVEN, Conn., May 8, 2025 - Rallybio Corporatio |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 08, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 8, 2025 |
Exhibit 99.1 Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT - RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy - - RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – NEW HAVEN, Conn., April 8, 2025 - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology c |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| March 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 13, 2025 |
Exhibit 99.1 Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates ̶ Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 ̶ – Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 ̶ ̶ $65.5 Million in Cash, Cash Equivalents, and Marketable Securities |
|
| March 13, 2025 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 RALLYBIO CORPORATION POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1. |
|
| March 13, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-266668 PROSPECTUS SUPPLEMENT (To Prospectus dated August 15, 2022) $9,550,000 Common Stock We previously entered into a sales agreement (the “original sales agreement”) with TD Securities (USA) LLC (“TD Cowen”), relating to shares of our common stock offered by a prospectus supplement dated August 15, 2022. On March |
|
| March 13, 2025 |
, 2025, by and between Rallybio Corporation and TD Securities (USA) LLC Exhibit 1.1 Execution Version AMENDMENT NO. 1 TO SALES AGREEMENT March 13, 2025 Rallybio Corporation 234 Church Street, Suite 120 New Haven, Connecticut 06510 Ladies and Gentlemen: Rallybio Corporation, a Delaware corporation (the “Company”), together with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (the “Agent”), are parties to that certain Sales Agreement dated August 8, 202 |
|
| March 13, 2025 |
Company Insider Trading Policy. Exhibit 19.1 Insider Trading Policy 1.Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Rallybio Corporation (the “Company”) and the handling of confidential information about the Company and the companies with which it does business. The Company’s Board of Directors (the “Board”) has adopted this Policy to promote compliance |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 25, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 12, 2025 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| November 12, 2024 |
RLYB / Rallybio Corporation / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 RALLYBIO CORP COMMON STOCK Cusip #75120L100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75120L100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,315,480 Item 6: 0 Item 7: 2,315,480 Item 8: 0 Item 9: 2,315 |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2024 |
Exhibit 99.1 Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates ̶ CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 ̶ ̶ $75.1 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2024 Provides Runway into Mid-2026 ̶ NEW HAVEN, Conn., November 7, 2024 - Rallybio Corporation (Nasdaq: RLYB) |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 8, 2024 |
Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 10, 2024, by and among Rallybio Corporation, a Delaware corporation (the “Company”), and the purchaser signatory hereto (the “Purchaser”). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof between the Company and the Pu |
|
| August 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, by and among Rallybio Corporation, a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). RECITALS A. The Company and the Purchaser are executing and delivering this Agree |
|
| August 8, 2024 |
Exhibit 10.2 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the registrant customarily and actually treats such information as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. FNAIT COLLABORATIONAGREEMENT This FNAIT Collaboration Agreement (“Agreement”) by and betwee |
|
| August 8, 2024 |
Exhibit 99.1 Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates ̶ On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 ̶ ̶ $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of June 30, 2024 Provides Runway into Mid-2026 ̶ NEW HAVEN, Conn., August 8, 2024 - Rallybio Corporation (Nasdaq |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 30, 2024 |
RLYB / Rallybio Corporation / Canaan XI L.P. - SC 13G/A Passive Investment SC 13G/A 1 d860329dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Rallybio Corporation (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 75120L 100 (CUSIP Number) July 29, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| July 30, 2024 |
RLYB / Rallybio Corporation / JOHNSON & JOHNSON Passive Investment SC 13G 1 rallybiosch13gforjjdc.htm CUSIP No. 72120L100 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )[1] Rallybio Corporation (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of S |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):July 23, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 23, 2024 |
Exhibit 10.1 CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of this day of , 2025 (the “Effective Date”) by and among Rallybio Corporation (“Rallybio”), a Delaware corporation, Rallybio, LLC (“Rallybio LLC”), a Delaware limited liability company, and Martin Mackay, Ph.D. (“Dr. Mackay”). Rallybio LLC is party to this Agreement solely for purposes of Se |
|
| May 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 16, 2024 |
United States securities and exchange commission logo May 16, 2024 Stephen Uden, M. |
|
| May 16, 2024 |
Rallybio Corporation 234 Church Street Suite 1020 New Haven, CT 06510 Rallybio Corporation 234 Church Street Suite 1020 New Haven, CT 06510 May 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 10, 2024 |
Exhibit 4.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 10, 2024, by and among Rallybio Corporation, a Delaware corporation (the “Company”), and the purchaser signatory hereto (the “Purchaser”). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof between the Company and the Pu |
|
| May 10, 2024 |
Exhibit 4.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, by and among Rallybio Corporation, a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). RECITALS A. The Company and the Purchaser are executing and delivering this Agreem |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024. Table of Contents As filed with the Securities and Exchange Commission on May 10, 2024. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2024 |
Exhibit 99.1 Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates ̶ On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 ̶ ̶ $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides Runway into Mid-2026 ̶ NEW HAVEN, Conn., May 9, 2024 - Rallybio Corporation (Nasdaq: |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 10, 2024 |
Exhibit 99.1 Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) ̶ Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson ̶ NEW HAVEN, Conn., April 10, 2024 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed t |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| March 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| March 12, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 RALLYBIO CORPORATION POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1. |
|
| March 12, 2024 |
Exhibit 99.1 Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results - Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212; Company to Proceed Forward with Clinical Trial Application Process in Europe - - Phase 2 Dose Confirmation Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT Expected to Initiate in 2H 2024 - - $109.9 mi |
|
| March 12, 2024 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Organization Rallybio, LLC Delaware Rallybio IPA, LLC Delaware Rallybio IPB, LLC Delaware IPC Research, LLC Delaware Rallybio IPE, LLC Delaware Rallybio IPF, LLC Delaware |
|
| February 14, 2024 |
RLYB / Rallybio Corporation / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Rallybio Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSI |
|
| February 12, 2024 |
SC 13D/A 1 d779190dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment 1)* Rallybio Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75120L 100 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco, CA 9 |
|
| February 9, 2024 |
RLYB / Rallybio Corporation / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 RALLYBIO CORP COMMON STOCK Cusip #75120L100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75120L100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,534,690 Item 6: 0 Item 7: 2,535,571 Item 8: 0 Item 9: 2,535 |
|
| February 6, 2024 |
Exhibit 99.1 Rallybio Announces Portfolio Prioritization and Provides Corporate Update ̶ Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases ̶ ̶ Anticipated cost savings, including a 45% workforce reduction, extends cash runway into mid-2026 – NEW HAVEN, Conn., Febru |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 2, 2024 |
RLYB / Rallybio Corporation / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A 1 d683049dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rallybio Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75120L100 (CUSIP Number) December 27, 2023 (Date of Event which Requires Filing of this Statement) Check |
|
| December 20, 2023 |
Exhibit 99.2 ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ RLYB116 • • • AE preferred term RLYB116 Placebo N=10 n (%) All N=40 n (%) 2 mg N=6 n (%) 10 mg N=6 n (%) 30 mg N=6 n (%) 100 mg N=6 n (%) 300 mg N=6 n (%) Gastrointestinal disorders Abdominal pain/discomfort 2 (33.3) 2 (33.3) 4 (10.0) Diarrhea 1 (16.7) 1 (16.7) 3 (50.0) 1 (10.0) 6 (15.0) Nausea/Vomiting 2 (33.3) 2 (5.0) General disorders and administration Fatigue/Le |
|
| December 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 20, 2023 |
Exhibit 99.1 Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 - 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing - - Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized My |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2023 |
Exhibit 99.1 Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates - RLYB212 Phase 1 Multiple Dose Cohort Complete and on Track for 4Q 2023 Data Release - - Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD on Track for 4Q 2023 Release - - $121.4 million cash, cash equivalents and marketable securities as of September 30, 2023 |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 8, 2023 |
Exhibit 99.1 Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates - RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 - - RLYB212 Phase 1 Multiple Dose Cohort Study Results Expected in 4Q 2023 - - Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 8, 2023 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) dated as of August 1, 2023 (the “Effective Date”) by and between Rallybio, LLC, a Delaware limited liability company (the “Company”), Rallybio Corporation, a Delaware corporation (“Parent”), and Stephen Uden (the “Executive”). This Agreement amends and restates in its e |
|
| August 8, 2023 |
Exhibit 10.2 1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) dated as of August 1, 2023 (the “Effective Date”) by and between Rallybio, LLC, a Delaware limited liability company (the “Company”), Rallybio Corporation, a Delaware corporation (“Parent”), and Martin W. Mackay (the “Executive”). This Agreement amends and restates in |
|
| June 29, 2023 |
Exhibit 99.1 Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023 - Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman - NEW HAVEN, Conn. June 29, 2023- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the develo |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2023 |
Rallybio Corporation 12,351,600 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-271748 PROSPECTUS Rallybio Corporation 12,351,600 Shares of Common Stock This prospectus relates to the disposition from time to time, in one or more offerings, of up to 12,351,600 shares of our common stock, par value $0.0001 per share, by the selling stockholders, including their transferees, pledgees, donees or succes |
|
| May 11, 2023 |
United States securities and exchange commission logo May 11, 2023 Martin Mackay, Ph. |
|
| May 11, 2023 |
RALLYBIO CORPORATION 234 Church Street, Suite 1020 New Haven, CT 06510 CORRESP RALLYBIO CORPORATION 234 Church Street, Suite 1020 New Haven, CT 06510 May 11, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| May 10, 2023 |
As filed with the Securities and Exchange Commission on May 10, 2023 S-8 As filed with the Securities and Exchange Commission on May 10, 2023 Registration No. |
|
| May 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 9, 2023 |
As filed with the Securities and Exchange Commission on May 9, 2023. S-3 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2023. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| May 9, 2023 |
Exhibit 99.1 Rallybio Reports First Quarter 2023 Financial Results - RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 - - Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 - - Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; S |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defin |
|
| March 6, 2023 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Organization Rallybio, LLC Delaware Rallybio IPA, LLC Delaware Rallybio IPB, LLC Delaware IPC Research, LLC Delaware Rallybio IPE, LLC Delaware Rallybio IPF, LLC Delaware |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40693 RALLYBIO CORPOR |
|
| March 6, 2023 |
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia - RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects - - Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT - - Company Expects to Present Results at a Scientific Conference in 2023 - NEW HAVEN, Conn. |
|
| March 6, 2023 |
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results - Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects – - Phase 1 Multiple Dose Cohort RLYB212 Study Initiated - - Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 - - $169. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 6, 2023 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the securities of Rallybio Corporation (“us,” “our,” “we” or the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is intended as a summary only and therefore is not a c |
|
| March 6, 2023 |
Exhibit 10.24 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 1, 2023 (the “Effective Date”) by and between Rallybio, LLC, a Delaware limited liability company (the “Company”), and Jonathan Lieber (the “Executive”). W I T N E S S E T H: WHEREAS, the Company desires to employ the Executive as the Chief Financial Officer and Treasurer of the Company; and WHEREAS, th |
|
| March 6, 2023 |
CONFIDENTIAL Exhibit 10.25 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the registrant customarily and actually treats such information as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT This Confidential Release and S |
|
| February 9, 2023 |
RLYB / Rallybio Holdings, LLC / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 RALLYBIO CORP COMMON STOCK Cusip #75120L100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75120L100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,245,181 Item 6: 0 Item 7: 3,245,425 Item 8: 0 Item 9: 3,245 |
|
| February 6, 2023 |
RLYB / Rallybio Holdings, LLC / New Leaf Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d356328dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rallybio Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check |
|
| February 1, 2023 |
RLYB / Rallybio Holdings, LLC / Canaan XI L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Rallybio Corporation (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 75120L 100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 31, 2023 |
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer NEW HAVEN, Conn. January 31, 2023—Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company’s Chief Fina |
|
| January 23, 2023 |
EX-99.1 2 tm233716d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement The undersigned persons, on January 23, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the Common Stock of Rallybio Corp. on December 31, 2022. Tekla Capital Management LLC By /s/ Laura Woodward Laura Woodward Daniel R. Omstead By /s/ Da |
|
| January 23, 2023 |
RLYB / Rallybio Holdings, LLC / Tekla Capital Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rallybio Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 75120L100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| December 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 RALLYBIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission |
|
| November 17, 2022 |
RLYB / Rallybio Holdings, LLC / Novo Holdings A/S - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rallybio Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75120L100 (CUSIP Number) November 15, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 14, 2022 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT RALLYBIO CORPORATION Warrant Shares: Initial Exercise Date: , 2022 Issue Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| November 14, 2022 |
EX-1.1 2 d407423dex11.htm EX-1.1 Exhibit 1.1 5,000,001 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,333,388 Shares of Common Stock Rallybio Corporation UNDERWRITING AGREEMENT November 10, 2022 J.P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 101 |
|
| November 14, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-266668 Prospectus supplement (To prospectus dated August 15, 2022) 5,000,001 shares of common stock Pre-funded warrants to purchase 3,333,388 shares of common stock We are offering 5,000,001 shares of our common stock in this offering and, in lieu of common stock to certain investors, pre-funded warrants to purchase |
|
| November 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 RALLYBIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2022 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| November 7, 2022 |
Exhibit 99.1 Rallybio Reports Third Quarter 2022 Financial Results - Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data expected in 1Q 2023 - - Positive 100 mg results of Phase 1 study of RLYB116 showed reduction of >99% in free C5 with the potential for weekly or less frequent dosing - NEW |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 28, 2022 |
Exhibit 99.1 Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia - Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA-1a positive platelets - - Proof-of-Concept Data Expected in 1Q 2023- NEW HAVEN, Conn. September 28, 2022?Ral |
|
| August 15, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-266668 PROSPECTUS SUPPLEMENT (To Prospectus dated August 15, 2022) $100,000,000 Common Stock We have entered into a sales agreement (the ?sales agreement?) with Cowen and Company, LLC (?Cowen?), relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agr |
|
| August 11, 2022 |
United States securities and exchange commission logo August 11, 2022 Michael Greco, Esq. |
|
| August 11, 2022 |
RALLYBIO CORPORATION 234 Church Street, Suite 1020 New Haven, CT 06510 CORRESP 1 filename1.htm RALLYBIO CORPORATION 234 Church Street, Suite 1020 New Haven, CT 06510 August 11, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Rallybio Corporation Registration Statement on Form S-3 (File No. 333-266668) Request for Acceleration Ladies and G |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022. Table of Contents As filed with the Securities and Exchange Commission on August 8, 2022. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| August 8, 2022 |
Sales Agreement, dated as of August 8, 2022, between Rallybio Corporation and Cowen and Company, LLC Exhibit 1.2 RALLYBIO CORPORATION $100,000,000 SALES AGREEMENT August 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Rallybio Corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreemen |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 8, 2022 |
Exhibit 99.1 Rallybio Reports Second Quarter 2022 Financial Results - Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets - - Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022- NEW HAVEN, Conn. August 8, 2022- Rallybio Corporation (Nasdaq: RLYB), a clinical-s |
|
| August 8, 2022 |
Exhibit 10.1 EXECUTION VERSION Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the registrant customarily and actually treats such information as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Portions of this Exhibit have been redacted because they are both (i) not |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 2, 2022 |
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors Exhibit 99.1 Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors NEW HAVEN, Conn. August 2, 2022- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to it |
|
| June 7, 2022 |
RLYB / Rallybio Holdings, LLC / 5AM Ventures V, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rallybio Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 993-8565 (Name, Address and Teleph |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 6, 2022 As filed with the Securities and Exchange Commission on June 6, 2022 Registration No. |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Rallybio Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 2, 2022 |
Exhibit 99.1 Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer -Company initiates an external search for its next Chief Financial Officer- NEW HAVEN, Conn., June 2, 2022 ? Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare di |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 10, 2022 |
Exhibit 99.2 Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi -Expands pipeline focus on rare benign hematological disorders- -Licensing agreement marks first business development transaction since IPO? NEW HAVEN, Conn. May 10, 2022- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and acceler |
|
| May 10, 2022 |
Exhibit 99.1 Rallybio Reports First Quarter 2022 Financial Results - Initiated Phase 1b proof-of-concept study for RLYB212 for the prevention of FNAIT; initial data expected in 3Q 2022 - - Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected in 2H 2022 - - Acquired RLYB331 from Sanofi, a potentially first-in-class antibody for the treatment of multiple severe anem |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 4, 2022 |
Exhibit 99.1 Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors -Tim Shannon, M.D. to resign from Rallybio?s Board of Directors effective at 2022 Annual Meeting of Shareholders- NEW HAVEN, Conn. April 4, 2022- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming ther |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 15, 2022 |
EX-4.3 2 rlyb-ex43.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the securities of Rallybio Corporation (“us,” “our,” “we” or the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is intended as a summary |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40693 RALLYBIO CORPOR |
|
| March 15, 2022 |
Exhibit 99.1 Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results - Phase 1b proof-of-concept study for RLYB212 in development for the prevention of FNAIT on track to commence in 2Q 2022; initial data expected in 3Q 2022 - - First healthy volunteers dosed in Phase 1 study of RLYB116; single dose safety, PK, and PD data expected in 2H 2022 - - Advancing preclinical development of EN |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2022 |
MARCH 2022 TAKING A DEVASTATING DISEASE ? AND DEVASTATING IT. We?re going there. Corporate Presentation Forward-Looking Statements?This presentation contains forward-looking statements that are based on management?s beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward-lookin |
|
| March 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 14, 2022 |
RLYB / Rallybio Holdings, LLC / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Rallybio Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSI |
|
| February 11, 2022 |
RLYB / Rallybio Holdings, LLC / New Leaf Ventures III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rallybio Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 11, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| February 8, 2022 |
Exhibit 99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that |
|
| February 8, 2022 |
RLYB / Rallybio Holdings, LLC / Canaan XI L.P. - SC 13G Passive Investment SC 13G 1 d274593dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rallybio Corporation (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 75120L 100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 8, 2022 |
Exhibit 24 Exhibit 24 2018 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the signature pages hereto |
|
| January 21, 2022 |
RLYB / Rallybio Holdings, LLC / Tekla Capital Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rallybio Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 75120L100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 21, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned persons, on January 21, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the Common Stock of Rallybio Corp. on December 31, 2021. Tekla Capital Management LLC By /s/ Laura Woodward Laura Woodward Daniel R. Omstead By /s/ Daniel R. Omstead Daniel R. Omstead |
|
| January 18, 2022 |
RLYB / Rallybio Holdings, LLC / TPG GP A, LLC - AMENDED SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rallybio Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75120L100 (CUSIP Number) Bradford Berenson TPG Inc. 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000 (Name, Address and Telep |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
Exhibit 99.1 Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights - Initiated FNAIT natural history study to inform frequency of FNAIT risk in broad population and support future potential registration trial - - On-track to announce in 4Q 2021 additional clinical data from ongoing Phase 1/2 study of RLYB211 for prevention of FNAIT - - Executing across pr |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 9, 2021 |
Exhibit 99.1 Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights ? Completed initial public offering for $92.7 million of gross proceeds ? ? Clinical proof-of-concept data for RLYB211 for the prevention of FNAIT was presented at the ISTH Virtual Congress; Additional Phase 1/2 data expected in 4Q 2021 ? ? On-track to initiate Phase 1 studies of RLYB212, |
|
| September 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2021 RALLYBIO CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 001-40693 85-1083789 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40693 RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 12, 2021 |
RLYB / Rallybio Holdings, LLC / 5AM Ventures V, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Rallybio Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 993-8565 (Name, Address and Telepho |
|
| August 12, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Rallybio Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75120L100 (CUSIP Number) Michael LaGatta TPG Global, LLC 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000 (Name, Address and Te |
|
| August 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Rallybio Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75120L 100 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name, Address and T |
|
| August 9, 2021 |
RLYB / Rallybio Holdings, LLC / VIKING GLOBAL INVESTORS LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Rallybio Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 75120L100 (CUSIP Number) July 29, |
|
| August 4, 2021 |
RLYB / Rallybio Holdings, LLC / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 RALLYBIO CORP COMMON STOCK Cusip #75120L100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75120L100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,556,878 Item 6: 0 Item 7: 2,891,173 Item 8: 0 Item 9: 2,891,173 Item 11: 9.266% |
|
| August 2, 2021 |
Exhibit 3.2 RALLYBIO CORPORATION AMENDED AND RESTATED BYLAWS SECTION 1 - STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of Rallybio Corporation, a Delaware corporation (the ?Corporation?), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the plac |
|
| August 2, 2021 |
As filed with the Securities and Exchange Commission on August 2, 2021 As filed with the Securities and Exchange Commission on August 2, 2021 Registration No. |
|
| August 2, 2021 |
Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), is made as of the 28th day of July, 2021, by and among Rallybio Corporation, a Delaware corporation (including Rallybio Corporation?s successors by merger, acquisition, reorganization or otherwise, the ?Company?), each of the investors listed on Schedule A hereto, any additional Investor who becomes a |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 RALLYBIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40693 85-1083789 (State or other jurisdiction of incorporation) (Commission File |
|
| August 2, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RALLYBIO CORPORATION Rallybio Corporation, a Delaware corporation (the ?Corporation?), hereby certifies that this Amended and Restated Certificate of Incorporation has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware (the ?DGCL?), and that: A. The name of the Corporatio |
|
| July 30, 2021 |
6,200,000 Shares Rallybio Corporation Common Stock Table of Contents Filed Pursuant to Rule 4242(b)(4) Registration No. 333-257655 Registration No. 333-258244 PROSPECTUS 6,200,000 Shares Rallybio Corporation Common Stock We are offering 6,200,000 shares of our common stock. This is an initial public offering. Prior to this offering, there has been no public market for our shares of common stock. The initial public offering price is $13.00 per shar |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 RALLYBIO CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-1083789 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2 |
|
| July 29, 2021 | ||
| July 28, 2021 |
As filed with the Securities and Exchange Commission on July 28, 2021 As filed with the Securities and Exchange Commission on July 28, 2021 Registration No. |
|
| July 28, 2021 |
July 28, 2021 Martin W. Mackay, Ph.D. Chief Executive Officer 234 Church Street, Suite 1020 New Haven, CT 06510 Re: Rallybio Corporation Registration Statement on Form S-1, as amended Exhibit Nos. 10.1-10.6 Filed July 2, 2021 File No. 333-257655 Dear Dr. Mackay: We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplem |
|
| July 26, 2021 |
RALLYBIO CORPORATION 234 Church Street Suite 1020 New Haven, CT 06510 CORRESP 1 filename1.htm RALLYBIO CORPORATION 234 Church Street Suite 1020 New Haven, CT 06510 July 26, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Celeste Murphy, Division of Corporation Finance Re: Rallybio Corporation Registration Statement on Form S-1 (File No. 333-257655) Request for |
|
| July 26, 2021 |
[Remainder of page intentionally left blank] Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, New York 10022 Evercore Group L. |
|
| July 22, 2021 |
EX-10.12 13 d99471dex1012.htm EX-10.12 Exhibit 10.12 RALLYBIO CORPORATION 2021 EQUITY INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and includes certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock |
|
| July 22, 2021 |
Exhibit 10.13 Name: [] Number of Shares of Stock subject to the Stock Option: [] Exercise Price Per Share: $[] Date of Grant: [] [Vesting Commencement Date:] [] RALLYBIO CORPORATION 2021 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT This agreement (this ?Agreement?) evidences a stock option granted by Rallybio Corporation, a Delaware corporation (the ?Company?), to the individual name |
|
| July 22, 2021 |
Exhibit 10.16 Name: [] Number of Restricted Stock Units: [] Date of Grant: [] [Vesting Commencement Date:] [] RALLYBIO CORPORATION 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT This agreement (this ?Agreement?) evidences a grant (the ?Award?) of Restricted Stock Units (?RSUs?) by Rallybio Corporation, a Delaware corporation (the ?Company?), to the individual named above (the ?Particip |
|
| July 22, 2021 |
As filed with the Securities and Exchange Commission on July 22, 2021. Table of Contents As filed with the Securities and Exchange Commission on July 22, 2021. |
